Cisplatin
(Synonyms: 顺铂; cis-Platinum; CDDP; cis-Diaminodichloroplatinum) 目录号 : GC11908
顺铂是最好的、最早的基于金属的化疗药物之一，用于治疗广泛的实体癌症，如睾丸癌、卵巢癌、膀胱癌、肺癌、宫颈癌、头颈部肿瘤和胃癌等。
Cas No.:15663-27-1
Sample solution is provided at 25 µL, 10mM.
Cisplatin is one of the best and first metal-based chemotherapeutic drugs, which is used for wide range of solid cancers such as testicular, ovarian, bladder, lung, cervical, head and neck cancer, gastric cancer and some other cancers. Studies confirmed that cisplatin exerts its anticancer activity by attacking more than one place. Cisplatin generally binds with genomic DNA (gDNA) or mitochondrial DNA (mtDNA) to create DNA lesions, block the production of DNA, mRNA and proteins, arrest DNA replication, activate several transduction pathways which finally led to necrosis or apoptosis.[1]
In vitro and in vivo experiments indicated that cisplatin induced cell resistance and cisplatin administrated rats exhibited increased creatinine, urea, and uric acid and this effect was more pronounced than in rats treated with gentamicin.[1][2]
References:
[1]. Stordal B, et al. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9.
[2]. Abouzed TK, et al. Assessment of gentamicin and cisplatin-induced kidney damage mediated via necrotic and apoptosis genes in albino rats. BMC Vet Res. 2021 Nov 16;17(1):350.
顺铂是最好的、最早的基于金属的化疗药物之一,用于治疗广泛的实体癌症,如睾丸癌、卵巢癌、膀胱癌、肺癌、宫颈癌、头颈部肿瘤和胃癌等。研究证实,顺铂通过攻击多个位置发挥其抗癌活性。通常情况下,顺铂与基因组DNA（gDNA）或线粒体DNA（mtDNA）结合形成DNA损伤,阻止DNA、mRNA和蛋白质的产生,阻滞DNA复制,并激活几条信号转导途径,最终导致坏死或凋亡。[1]
体外和体内实验表明,顺铂会导致细胞耐药性增强,给予顺铂的大鼠显示出肌酐、尿素和尿酸水平升高的现象,而这种影响比使用庆大霉素治疗的大鼠更为显著。
| Cell experiment [1]: | |
|
Cell lines |
H69 SCLC cells |
|
Reaction Conditions |
H69 SCLC cells were treated with100 ng/ml cisplatin, to produce the H69-CP or 200 ng/ml cisplatin to obtain the H69CIS200 cells. These doses are below an IC50 for cisplatin and are within the range achieved in the clinical use of cisplatin. |
|
Applications |
The cells were 2- to 4-fold resistant to cisplatin, which could be used to further study the resistance mechanism. |
| Animal experiment [2]: | |
|
Animal models |
Adult male Wistar rats, weighing 160-200 g |
|
Preparation Method |
The rats were kept at 25 °C on a 12/12 h light/dark cycle, in single plastic cages with bedding, with access to standard rat food and water ad libitum. Rats were randomly assigned to one of three groups: 1) Control group, who received no intervention and maintained a regular diet; 2) Gentamicin group, who were administered 100 mg/kg BW IP gentamicin daily for 7 days; 3) Cisplatin group, who were administered 1.5 mg/kg BW IP cisplatin twice a week for 3 weeks. |
|
Dosage form |
1.5 mg/kg |
|
Applications |
Cisplatin and gentamicin could significantly elevate serum levels of creatinine, uric acid, and urea, with cisplatin showing higher elevation. Cisplatin could also significantly decrease the GSH and GPx levels. |
|
References: [1]. Stordal B, et al. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9. [2]. Abouzed TK, et al. Assessment of gentamicin and cisplatin-induced kidney damage mediated via necrotic and apoptosis genes in albino rats. BMC Vet Res. 2021 Nov 16;17(1):350. |
|
| Cas No. | 15663-27-1 | SDF | |
| 别名 | 顺铂; cis-Platinum; CDDP; cis-Diaminodichloroplatinum | ||
| 化学名 | azane;dichloroplatinum(2+) | ||
| Canonical SMILES | N.N.Cl[Pt+2]Cl | ||
| 分子式 | Cl2H6N2Pt | 分子量 | 300.05 |
| 溶解度 | 5 mg/mL in DMF (16.66 mM; DMSO can inactivate Cisplatin's activity), 1 mg/mL in Water (3.33 mM; DMSO can inactivate Cisplatin's activity) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3328 mL | 16.6639 mL | 33.3278 mL |
| 5 mM | 0.6666 mL | 3.3328 mL | 6.6656 mL |
| 10 mM | 0.3333 mL | 1.6664 mL | 3.3328 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet